XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

NCT00417079 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

755

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Prostatic Neoplasms

Interventions

DRUG: cabazitaxel (XRP6258) (RPR116258)
DRUG: mitoxantrone
DRUG: prednisone

Sponsor

Sanofi